Salix Pharms., Ltd. v. Norwich Pharms. Inc. – Xifaxan® (Rifaximin)

July 31, 2024

Case Name: Salix Pharms., Ltd. v. Norwich Pharms. Inc., No. 2022-2153, 2023-1952, 2024 WL 1561195 (Fed. Cir. Apr. 11, 2024) (Circuit Judges Lourie, Chen, and Cunningham presiding; Opinion by Lourie, J.; Dissenting-in-part Opinion by Cunningham, J.) (Appeal from D. Del., Andrews. J.)….
By: Robins Kaplan LLP

Salix Pharms., Ltd. v. Norwich Pharms. Inc. – Xifaxan® (Rifaximin)

Federal Circuit Patent Watch: Ordering In-Person Appearance to Testify Regarding Potential Fraud on the Court is within Court’s Inherent Authority

Commerce Department Expands Export Jurisdiction for Foreign-Made Items to Iran: Foreign Direct Product Rule Update